Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Healthcare Shares
Brokers say these defensive ASX 200 healthcare shares are buys
52-Week Highs
Big Wednesday: 12 ASX 200 stocks cracking new 52-week highs
Blue Chip Shares
Want to boost your portfolio with ASX blue chips? Analysts say buy these shares
Dividend Investing
6 ASX 200 shares with ex-dividend dates in the next week
Healthcare Shares
Buy these excellent ASX 200 healthcare shares: Goldman Sachs
Investing Strategies
How I'd invest $20,000 in ASX 200 shares to aim for a million
Blue Chip Shares
2 ASX 200 shares to buy post-results: Morgans
Broker Notes
4 ASX 200 shares rerated by brokers following earnings results
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Why Cochlear, GUD, Netwealth, and Wesfarmers shares are charging higher
Healthcare Shares
Cochlear share price surges 6% on solid half and buyback
Blue Chip Shares
Why experts say these ASX 200 blue chip shares are buys
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.